{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:07:55Z","timestamp":1787584075869,"version":"build-2736575974"},"reference-count":160,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s10620-024-08774-2","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T09:34:56Z","timestamp":1737970496000},"page":"919-942","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Emerging Frontiers in Colorectal Cancer Therapy: From Targeted Molecules to Immunomodulatory Breakthroughs and Cell-Based Approaches"],"prefix":"10.1007","volume":"70","author":[{"given":"Nayeralsadat","family":"Fatemi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyedeh Nasim","family":"Mirbahari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Tierling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Sanjabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shabnam","family":"Shahrivari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandana","family":"AmeliMojarad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melika","family":"Amelimojarad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meygol","family":"Mirzaei Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parsa","family":"Nobaveh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Totonchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8914-004X","authenticated-orcid":false,"given":"Ehsan","family":"Nazemalhosseini Mojarad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,27]]},"reference":[{"key":"8774_CR1","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.soc.2014.03.003","volume":"23","author":"P Alluri","year":"2014","unstructured":"Alluri P, Newman LA. Basal-like and triple-negative breast cancers: searching for positives among many negatives. Surg Oncol Clin N Am 2014;23:567\u2013577. https:\/\/doi.org\/10.1016\/j.soc.2014.03.003.","journal-title":"Surg Oncol Clin N Am"},{"key":"8774_CR2","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S2468-1253(22)00044-9","volume":"7","author":"GBDCC Collaborators","year":"2022","unstructured":"Collaborators GBDCC. Global, regional, and national burden of colorectal cancer and its risk factors, 1990\u20132019: a systematic analysis for the global burden of disease study 2019. Lancet Gastroenterol Hepatol 2022;7:627\u2013647. https:\/\/doi.org\/10.1016\/S2468-1253(22)00044-9.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"8774_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11071017","author":"FDE De Palma","year":"2019","unstructured":"De Palma FDE, D\u2019Argenio V, Pol J, Kroemer G, Maiuri MC, Salvatore F. The molecular hallmarks of the serrated pathway in colorectal cancer. Cancers (Basel). 2019. https:\/\/doi.org\/10.3390\/cancers11071017.","journal-title":"Cancers (Basel)"},{"key":"8774_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910260","author":"C Stefani","year":"2021","unstructured":"Stefani C, Miricescu D, Stanescu S II et al. Growth factors, PI3K\/AKT\/mTOR and MAPK signaling pathways in colorectal cancer pathogenesis: where are we now? Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms221910260.","journal-title":"Int J Mol Sci"},{"key":"8774_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12051171","author":"LJ Fennell","year":"2020","unstructured":"Fennell LJ, Kane A, Liu C et al. APC mutation marks an aggressive subtype of BRAF mutant colorectal cancers. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12051171.","journal-title":"Cancers (Basel)"},{"key":"8774_CR6","doi-asserted-by":"publisher","first-page":"4428","DOI":"10.3748\/wjg.v24.i39.4428","volume":"24","author":"A Tiwari","year":"2018","unstructured":"Tiwari A, Saraf S, Verma A, Panda PK, Jain SK. Novel targeting approaches and signaling pathways of colorectal cancer: an insight. World J Gastroenterol 2018;24:4428\u20134435. https:\/\/doi.org\/10.3748\/wjg.v24.i39.4428.","journal-title":"World J Gastroenterol"},{"key":"8774_CR7","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1200\/JCO.2017.75.3780","volume":"36","author":"JD Hainsworth","year":"2018","unstructured":"Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C et al. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from mypathway, an open-label, phase iia multiple basket study. J Clin Oncol 2018;36:536\u2013542. https:\/\/doi.org\/10.1200\/JCO.2017.75.3780.","journal-title":"J Clin Oncol"},{"key":"8774_CR8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3904\/kjim.1995.10.1.25","volume":"10","author":"JY Jin","year":"1995","unstructured":"Jin JY, Kim DW, Lee JW, Han CW, Min WS, Park CW et al. Immune suppression therapy in aplastic anemia: influencing factors on response and survival. Korean J Intern Med 1995;10:25\u201331. https:\/\/doi.org\/10.3904\/kjim.1995.10.1.25.","journal-title":"Korean J Intern Med"},{"key":"8774_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13010086","author":"M Kumar","year":"2020","unstructured":"Kumar M, Thangavel C, Becker RC, Sadayappan S. Monoclonal antibody-based immunotherapy and its role in the development of cardiac toxicity. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers13010086.","journal-title":"Cancers (Basel)"},{"key":"8774_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.649863","volume":"12","author":"L Zhan","year":"2021","unstructured":"Zhan L, Feng HF, Liu HQ et al. Immune checkpoint inhibitors-related thyroid dysfunction: epidemiology, clinical presentation, possible pathogenesis, and management. Front Endocrinol (Lausanne) 2021;12:649863. https:\/\/doi.org\/10.3389\/fendo.2021.649863.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"8774_CR11","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.2174\/092986706777585059","volume":"13","author":"G Ranieri","year":"2006","unstructured":"Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem 2006;13:1845\u20131857. https:\/\/doi.org\/10.2174\/092986706777585059.","journal-title":"Curr Med Chem"},{"key":"8774_CR12","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1186\/s13046-021-02130-2","volume":"40","author":"J Zhou","year":"2021","unstructured":"Zhou J, Ji Q, Li Q. Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies. J Exp Clin Cancer Res 2021;40:328. https:\/\/doi.org\/10.1186\/s13046-021-02130-2.","journal-title":"J Exp Clin Cancer Res"},{"key":"8774_CR13","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335\u20132342. https:\/\/doi.org\/10.1056\/NEJMoa032691.","journal-title":"N Engl J Med"},{"key":"8774_CR14","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1111\/bcp.14472","volume":"87","author":"M Rouyer","year":"2021","unstructured":"Rouyer M, Francois E, Sa Cunha A et al. Effectiveness of first-line cetuximab in wild-type RAS metastatic colorectal cancer according to tumour BRAF mutation status from the EREBUS cohort. Br J Clin Pharmacol 2021;87:1120\u20131128. https:\/\/doi.org\/10.1111\/bcp.14472.","journal-title":"Br J Clin Pharmacol"},{"key":"8774_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.798515","volume":"12","author":"L Wei","year":"2022","unstructured":"Wei L, Lin Z, Xie S et al. Complete response with cetuximab-based treatment of metastatic colorectal cancers: two case reports and literature review. Front Oncol 2022;12:798515. https:\/\/doi.org\/10.3389\/fonc.2022.798515.","journal-title":"Front Oncol"},{"key":"8774_CR16","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1200\/JCO.20.01994","volume":"39","author":"S Kopetz","year":"2021","unstructured":"Kopetz S, Guthrie KA, Morris VK, Lenz HJ, Magliocco AM, Maru D et al. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406). J Clin Oncol 2021;39:285\u2013294. https:\/\/doi.org\/10.1200\/JCO.20.01994.","journal-title":"J Clin Oncol"},{"key":"8774_CR17","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1001\/jama.2023.4428","volume":"329","author":"J Watanabe","year":"2023","unstructured":"Watanabe J, Muro K, Shitara K, Yamazaki K, Shiozawa M, Ohori H et al. Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial. JAMA 2023;329:1271\u20131282. https:\/\/doi.org\/10.1001\/jama.2023.4428.","journal-title":"JAMA"},{"key":"8774_CR18","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H et al. Immune checkpoint inhibitors in cancer therapy. Curr Oncol 2022;29:3044\u20133060. https:\/\/doi.org\/10.3390\/curroncol29050247.","journal-title":"Curr Oncol"},{"key":"8774_CR19","doi-asserted-by":"publisher","first-page":"e30561","DOI":"10.1097\/md.0000000000030561","volume":"101","author":"R He","year":"2022","unstructured":"He R, Zhao X, Liu J, Zhou Y, Zhang X, Cheng F. PD-1 and CTLA-4 inhibitors in combination vs alone for the treatment of advanced melanoma: a systematic review and meta-analysis. Medicine (Baltimore) 2022;101:e30561. https:\/\/doi.org\/10.1097\/md.0000000000030561.","journal-title":"Medicine (Baltimore)"},{"key":"8774_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14204974","author":"B Borelli","year":"2022","unstructured":"Borelli B, Antoniotti C, Carullo M, Germani MM, Conca V, Masi G. Immune-checkpoint inhibitors (ICIs) in metastatic colorectal cancer (mCRC) patients beyond microsatellite instability. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14204974.","journal-title":"Cancers (Basel)"},{"key":"8774_CR21","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3389\/fimmu.2013.00114","volume":"4","author":"S Awate","year":"2013","unstructured":"Awate S, Babiuk LA, Mutwiri G. Mechanisms of action of adjuvants. Front Immunol 2013;4:114. https:\/\/doi.org\/10.3389\/fimmu.2013.00114.","journal-title":"Front Immunol"},{"key":"8774_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.942235","volume":"13","author":"W Jia","year":"2022","unstructured":"Jia W, Zhang T, Huang H et al. Colorectal cancer vaccines: the current scenario and future prospects. Front Immunol 2022;13:942235. https:\/\/doi.org\/10.3389\/fimmu.2022.942235.","journal-title":"Front Immunol"},{"key":"8774_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","volume":"20","author":"L Miao","year":"2021","unstructured":"Miao L, Zhang Y, Huang L. mRNA vaccine for cancer immunotherapy. Mol Cancer 2021;20:41. https:\/\/doi.org\/10.1186\/s12943-021-01335-5.","journal-title":"Mol Cancer"},{"key":"8774_CR24","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","volume":"26","author":"M Chalabi","year":"2020","unstructured":"Chalabi M, Fanchi LF, Dijkstra KK et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med 2020;26:566\u2013576. https:\/\/doi.org\/10.1038\/s41591-020-0805-8.","journal-title":"Nat Med"},{"key":"8774_CR25","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.3390\/ph16071054","volume":"16","author":"M Lekshmy","year":"2023","unstructured":"Lekshmy M, Dhanya CR, Smrithi JS et al. Peptide vaccines as therapeutic and prophylactic agents for female-specific cancers: the current landscape. Pharmaceuticals 2023;16:1054.","journal-title":"Pharmaceuticals"},{"key":"8774_CR26","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","volume":"386","author":"A Cercek","year":"2022","unstructured":"Cercek A, Lumish M, Sinopoli J et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med 2022;386:2363\u20132376. https:\/\/doi.org\/10.1056\/NEJMoa2201445.","journal-title":"N Engl J Med"},{"key":"8774_CR27","doi-asserted-by":"publisher","first-page":"D607","DOI":"10.1093\/nar\/gky1131","volume":"47","author":"D Szklarczyk","year":"2019","unstructured":"Szklarczyk D, Gable AL, Lyon D et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res 2019;47:D607-d613. https:\/\/doi.org\/10.1093\/nar\/gky1131.","journal-title":"Nucleic Acids Res"},{"key":"8774_CR28","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.40742","volume":"15","author":"MA Zolaly","year":"2023","unstructured":"Zolaly MA, Mahallawi W, Khawaji ZY, Alahmadi MA. The clinical advances of oncolytic viruses in cancer immunotherapy. Cureus 2023;15:e40742. https:\/\/doi.org\/10.7759\/cureus.40742.","journal-title":"Cureus"},{"key":"8774_CR29","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1158\/1078-0432.CCR-20-2385","volume":"27","author":"J Jiffry","year":"2021","unstructured":"Jiffry J, Thavornwatanayong T, Rao D et al. Oncolytic reovirus (pelareorep) induces autophagy in kras-mutated colorectal cancer. Clin Cancer Res 2021;27:865\u2013876. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2385.","journal-title":"Clin Cancer Res"},{"key":"8774_CR30","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1186\/s12885-020-07038-2","volume":"20","author":"R Parakrama","year":"2020","unstructured":"Parakrama R, Fogel E, Chandy C et al. Immune characterization of metastatic colorectal cancer patients post reovirus administration. BMC Cancer 2020;20:569. https:\/\/doi.org\/10.1186\/s12885-020-07038-2.","journal-title":"BMC Cancer"},{"key":"8774_CR31","doi-asserted-by":"publisher","first-page":"2004433","DOI":"10.1002\/advs.202004433","volume":"8","author":"C Liu","year":"2021","unstructured":"Liu C, Chu D, Kalantar-Zadeh K, George J, Young HA, Liu G. Cytokines: from clinical significance to quantification. Advanced Science 2021;8:2004433.","journal-title":"Advanced Science"},{"key":"8774_CR32","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028472","volume":"10","author":"TA Waldmann","year":"2018","unstructured":"Waldmann TA. Cytokines in cancer immunotherapy. Cold Spring Harbor perspectives in biology 2018;10:a028472.","journal-title":"Cold Spring Harbor perspectives in biology"},{"key":"8774_CR33","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.3390\/cancers3043856","volume":"3","author":"S Lee","year":"2011","unstructured":"Lee S, Margolin K. Cytokines in cancer immunotherapy. Cancers (Basel) 2011;3:3856\u20133893. https:\/\/doi.org\/10.3390\/cancers3043856.","journal-title":"Cancers (Basel)"},{"key":"8774_CR34","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/cac2.12295","volume":"42","author":"AA Bhat","year":"2022","unstructured":"Bhat AA, Nisar S, Singh M et al. Cytokine- and chemokine-induced inflammatory colorectal tumor microenvironment: emerging avenue for targeted therapy. Cancer Commun (Lond) 2022;42:689\u2013715. https:\/\/doi.org\/10.1002\/cac2.12295.","journal-title":"Cancer Commun (Lond)"},{"key":"8774_CR35","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.smim.2010.04.007","volume":"22","author":"TW Dubensky Jr","year":"2010","unstructured":"Dubensky TW Jr, Reed SG. Adjuvants for cancer vaccines. Semin Immunol 2010;22:155\u2013161. https:\/\/doi.org\/10.1016\/j.smim.2010.04.007.","journal-title":"Semin Immunol"},{"key":"8774_CR36","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.cellimm.2014.12.012","volume":"293","author":"G Ni","year":"2015","unstructured":"Ni G, Wang T, Walton S et al. Manipulating IL-10 signalling blockade for better immunotherapy. Cell Immunol 2015;293:126\u2013129. https:\/\/doi.org\/10.1016\/j.cellimm.2014.12.012.","journal-title":"Cell Immunol"},{"key":"8774_CR37","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2174\/187221107780831897","volume":"1","author":"Y Perrie","year":"2007","unstructured":"Perrie Y, Kirby D, Bramwell VW, Mohammed AR. Recent developments in particulate-based vaccines. Recent Pat Drug Deliv Formul 2007;1:117\u2013129. https:\/\/doi.org\/10.2174\/187221107780831897.","journal-title":"Recent Pat Drug Deliv Formul"},{"key":"8774_CR38","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1016\/j.vaccine.2017.03.067","volume":"35","author":"TJ Goodwin","year":"2017","unstructured":"Goodwin TJ, Huang L. Investigation of phosphorylated adjuvants co-encapsulated with a model cancer peptide antigen for the treatment of colorectal cancer and liver metastasis. Vaccine 2017;35:2550\u20132557. https:\/\/doi.org\/10.1016\/j.vaccine.2017.03.067.","journal-title":"Vaccine"},{"key":"8774_CR39","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1039\/c5sc03892h","volume":"7","author":"M Skwarczynski","year":"2016","unstructured":"Skwarczynski M, Toth I. Peptide-based synthetic vaccines. Chem Sci 2016;7:842\u2013854. https:\/\/doi.org\/10.1039\/c5sc03892h.","journal-title":"Chem Sci"},{"key":"8774_CR40","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.actbio.2021.05.003","volume":"133","author":"CL O'Neill","year":"2021","unstructured":"O\u2019Neill CL, Shrimali PC, Clapacs ZE, Files MA, Rudra JS. Peptide-based supramolecular vaccine systems. Acta Biomaterialia 2021;133:153\u2013167. https:\/\/doi.org\/10.1016\/j.actbio.2021.05.003.","journal-title":"Acta Biomaterialia"},{"key":"8774_CR41","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1600-065X.2010.00979.x","volume":"239","author":"CA Klebanoff","year":"2011","unstructured":"Klebanoff CA, Acquavella N, Yu Z, Restifo NP. Therapeutic cancer vaccines: are we there yet? Immunol Rev 2011;239:27\u201344. https:\/\/doi.org\/10.1111\/j.1600-065X.2010.00979.x.","journal-title":"Immunol Rev"},{"key":"8774_CR42","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/1479-5876-12-108","volume":"12","author":"S Hazama","year":"2014","unstructured":"Hazama S, Nakamura Y, Tanaka H et al. A phase IotaI study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study). J Transl Med 2014;12:108. https:\/\/doi.org\/10.1186\/1479-5876-12-108.","journal-title":"J Transl Med"},{"key":"8774_CR43","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.clim.2016.03.015","volume":"166\u2013167","author":"M Murahashi","year":"2016","unstructured":"Murahashi M, Hijikata Y, Yamada K et al. Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors. Clin Immunol 2016;166\u2013167:48\u201358. https:\/\/doi.org\/10.1016\/j.clim.2016.03.015.","journal-title":"Clin Immunol"},{"key":"8774_CR44","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1615\/CritRevImmunol.v37.i2-6.140","volume":"37","author":"E Manickan","year":"2017","unstructured":"Manickan E, Karem KL, Rouse BT. DNA vaccines\u2014a modern gimmick or a boon to vaccinology? Crit Rev Immunol 2017;37:483\u2013498. https:\/\/doi.org\/10.1615\/CritRevImmunol.v37.i2-6.140.","journal-title":"Crit Rev Immunol"},{"key":"8774_CR45","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12575-021-00147-7","volume":"23","author":"A Azadi","year":"2021","unstructured":"Azadi A, Golchini A, Delazar S et al. Recent advances on immune targeted therapy of colorectal cancer using bi-specific antibodies and therapeutic vaccines. Biol Proced Online 2021;23:13. https:\/\/doi.org\/10.1186\/s12575-021-00147-7.","journal-title":"Biol Proced Online"},{"key":"8774_CR46","doi-asserted-by":"publisher","first-page":"6817","DOI":"10.1016\/j.vaccine.2010.12.063","volume":"29","author":"C Staff","year":"2011","unstructured":"Staff C, Mozaffari F, Haller BK, Wahren B, Liljefors M. A phase I safety study of plasmid DNA immunization targeting carcinoembryonic antigen in colorectal cancer patients. Vaccine 2011;29:6817\u20136822. https:\/\/doi.org\/10.1016\/j.vaccine.2010.12.063.","journal-title":"Vaccine"},{"key":"8774_CR47","doi-asserted-by":"publisher","first-page":"205873921876814","DOI":"10.1177\/2058739218768144","volume":"16","author":"S Huang","year":"2018","unstructured":"Huang S, Yu X. Antitumor immunity of DNA vaccine based on CTLA-4 fused with HER2 against colon carcinoma. European Journal of Inflammation 2018;16:2058739218768144. https:\/\/doi.org\/10.1177\/2058739218768144.","journal-title":"European Journal of Inflammation"},{"key":"8774_CR48","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3389\/fimmu.2019.00594","volume":"10","author":"C Zhang","year":"2019","unstructured":"Zhang C, Maruggi G, Shan H, Li J. Advances in mRNA vaccines for infectious diseases. Front Immunol 2019;10:594. https:\/\/doi.org\/10.3389\/fimmu.2019.00594.","journal-title":"Front Immunol"},{"key":"8774_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2021.718753","volume":"9","author":"T Liu","year":"2021","unstructured":"Liu T, Liang Y, Huang L. Development and delivery systems of mRNA vaccines. Front Bioeng Biotechnol 2021;9:718753. https:\/\/doi.org\/10.3389\/fbioe.2021.718753.","journal-title":"Front Bioeng Biotechnol"},{"key":"8774_CR50","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/14712598.2020.1815704","volume":"21","author":"E Faghfuri","year":"2021","unstructured":"Faghfuri E, Pourfarzi F, Faghfouri AH, Abdoli Shadbad M, Hajiasgharzadeh K, Baradaran B. Recent developments of RNA-based vaccines in cancer immunotherapy. Expert Opin Biol Ther 2021;21:201\u2013218. https:\/\/doi.org\/10.1080\/14712598.2020.1815704.","journal-title":"Expert Opin Biol Ther"},{"key":"8774_CR51","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.biomaterials.2015.03.024","volume":"54","author":"C Li","year":"2015","unstructured":"Li C, Liang S, Zhang C et al. Allogenic dendritic cell and tumor cell fused vaccine for targeted imaging and enhanced immunotherapeutic efficacy of gastric cancer. Biomaterials 2015;54:177\u2013187. https:\/\/doi.org\/10.1016\/j.biomaterials.2015.03.024.","journal-title":"Biomaterials"},{"key":"8774_CR52","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1586\/14760584.4.3.329","volume":"4","author":"S Mosolits","year":"2005","unstructured":"Mosolits S, Nilsson B, Mellstedt H. Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials. Expert Rev Vaccines 2005;4:329\u2013350. https:\/\/doi.org\/10.1586\/14760584.4.3.329.","journal-title":"Expert Rev Vaccines"},{"key":"8774_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10060186","author":"M Takamura-Ishii","year":"2018","unstructured":"Takamura-Ishii M, Nakaya T, Hagiwara K. Regulation of constitutive interferon-stimulated genes (Isgs) in tumor cells contributes to enhanced antitumor response of newcastle disease virus-infected tumor vaccines. Cancers (Basel). 2018. https:\/\/doi.org\/10.3390\/cancers10060186.","journal-title":"Cancers (Basel)"},{"key":"8774_CR54","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1080\/1744666X.2016.1226132","volume":"13","author":"J Berry","year":"2017","unstructured":"Berry J, Vreeland T, Trappey A et al. Cancer vaccines in colon and rectal cancer over the last decade: lessons learned and future directions. Expert Rev Clin Immunol 2017;13:235\u2013245. https:\/\/doi.org\/10.1080\/1744666X.2016.1226132.","journal-title":"Expert Rev Clin Immunol"},{"key":"8774_CR55","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1038\/sj.bjc.6600254","volume":"86","author":"A Baars","year":"2002","unstructured":"Baars A, Claessen AM, Wagstaff J et al. A phase II study of active specific immunotherapy and 5-FU\/Leucovorin as adjuvant therapy for stage III colon carcinoma. Br J Cancer 2002;86:1230\u20131234. https:\/\/doi.org\/10.1038\/sj.bjc.6600254.","journal-title":"Br J Cancer"},{"key":"8774_CR56","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13148-021-01014-8","volume":"13","author":"KM Bever","year":"2021","unstructured":"Bever KM, Thomas DL 2nd, Zhang J et al. A feasibility study of combined epigenetic and vaccine therapy in advanced colorectal cancer with pharmacodynamic endpoint. Clin Epigenetics 2021;13:25. https:\/\/doi.org\/10.1186\/s13148-021-01014-8.","journal-title":"Clin Epigenetics"},{"key":"8774_CR57","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.136368","author":"VM Kim","year":"2020","unstructured":"Kim VM, Pan X, Soares KC et al. Neoantigen-based EpiGVAX vaccine initiates antitumor immunity in colorectal cancer. JCI Insight. 2020. https:\/\/doi.org\/10.1172\/jci.insight.136368.","journal-title":"JCI Insight"},{"key":"8774_CR58","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/sim.7203","volume":"37","author":"J Theiler","year":"2018","unstructured":"Theiler J, Korber B. Graph-based optimization of epitope coverage for vaccine antigen design. Stat Med 2018;37:181\u2013194. https:\/\/doi.org\/10.1002\/sim.7203.","journal-title":"Stat Med"},{"key":"8774_CR59","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1182\/blood-2006-12-061309","volume":"110","author":"Y Chung","year":"2007","unstructured":"Chung Y, Qin H, Kang CY, Kim S, Kwak LW, Dong C. An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity. Blood 2007;110:2013\u20132019. https:\/\/doi.org\/10.1182\/blood-2006-12-061309.","journal-title":"Blood"},{"key":"8774_CR60","doi-asserted-by":"publisher","first-page":"847","DOI":"10.2217\/imt.10.56","volume":"2","author":"ME Turnis","year":"2010","unstructured":"Turnis ME, Rooney CM. Enhancement of dendritic cells as vaccines for cancer. Immunotherapy 2010;2:847\u2013862. https:\/\/doi.org\/10.2217\/imt.10.56.","journal-title":"Immunotherapy"},{"key":"8774_CR61","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1586\/14760584.4.4.503","volume":"4","author":"H Sugiyama","year":"2005","unstructured":"Sugiyama H. Cancer immunotherapy targeting Wilms\u2019 tumor gene WT1 product. Expert Rev Vaccines 2005;4:503\u2013512. https:\/\/doi.org\/10.1586\/14760584.4.4.503.","journal-title":"Expert Rev Vaccines"},{"key":"8774_CR62","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.15_suppl.3048","author":"J Maurel","year":"2015","unstructured":"Maurel J, Caballero-Ba\u00f1os M, Mila J et al. Phase II randomized trial of autologous tumor lysate dendritic cell vaccine (ADC) plus best supportive care (BSC) compared with BSC, in pre-treated advanced colorectal cancer patients. Journal of Clinical Oncology. 2015. https:\/\/doi.org\/10.1200\/jco.2015.33.15_suppl.3048.","journal-title":"Journal of Clinical Oncology"},{"key":"8774_CR63","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3390\/biomedicines3040304","volume":"3","author":"Y Higuchi","year":"2015","unstructured":"Higuchi Y, Koya T, Yuzawa M et al. Enzyme-linked immunosorbent spot assay for the detection of wilms\u2019 tumor 1-specific t cells induced by dendritic cell vaccination. Biomedicines 2015;3:304\u2013315. https:\/\/doi.org\/10.3390\/biomedicines3040304.","journal-title":"Biomedicines"},{"key":"8774_CR64","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s40425-018-0405-z","volume":"6","author":"J Rodriguez","year":"2018","unstructured":"Rodriguez J, Castanon E, Perez-Gracia JL et al. A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis. J Immunother Cancer 2018;6:96. https:\/\/doi.org\/10.1186\/s40425-018-0405-z.","journal-title":"J Immunother Cancer"},{"key":"8774_CR65","doi-asserted-by":"publisher","first-page":"7726","DOI":"10.1158\/1078-0432.CCR-09-1537","volume":"15","author":"HC Toh","year":"2009","unstructured":"Toh HC, Wang WW, Chia WK et al. Clinical benefit of allogeneic melanoma cell lysate-pulsed autologous dendritic cell vaccine in MAGE-positive colorectal cancer patients. Clin Cancer Res 2009;15:7726\u20137736. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-1537.","journal-title":"Clin Cancer Res"},{"key":"8774_CR66","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/s1470-2045(21)00090-5","volume":"22","author":"MJ van den Bent","year":"2021","unstructured":"van den Bent MJ, Tesileanu CMS, Wick W et al. Adjuvant and concurrent temozolomide for 1p\/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053\u201322054): second interim analysis of a randomised, open-label, phase 3 study. Lancet Oncol 2021;22:813\u2013823. https:\/\/doi.org\/10.1016\/s1470-2045(21)00090-5.","journal-title":"Lancet Oncol"},{"key":"8774_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105374","volume":"164","author":"AL Wooster","year":"2021","unstructured":"Wooster AL, Girgis LH, Brazeale H, Anderson TS, Wood LM, Lowe DB. Dendritic cell vaccine therapy for colorectal cancer. Pharmacol Res 2021;164:105374. https:\/\/doi.org\/10.1016\/j.phrs.2020.105374.","journal-title":"Pharmacol Res"},{"key":"8774_CR68","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1038\/s41598-022-07305-1","volume":"12","author":"S Maruoka","year":"2022","unstructured":"Maruoka S, Ojima T, Iwamoto H, Kitadani J, Tabata H, Tominaga S et al. Tumor RNA transfected DCs derived from iPS cells elicit cytotoxicity against cancer cells induced from colorectal cancer patients in vitro. Sci Rep 2022;12:3295. https:\/\/doi.org\/10.1038\/s41598-022-07305-1.","journal-title":"Sci Rep"},{"key":"8774_CR69","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3389\/fimmu.2018.00276","volume":"9","author":"E Panagioti","year":"2018","unstructured":"Panagioti E, Klenerman P, Lee LN, van der Burg SH, Arens R. Features of effective T cell-inducing vaccines against chronic viral infections. Front Immunol 2018;9:276. https:\/\/doi.org\/10.3389\/fimmu.2018.00276.","journal-title":"Front Immunol"},{"key":"8774_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20143403","author":"S Jiang","year":"2019","unstructured":"Jiang S, Good D, Wei MQ. Vaccinations for colorectal cancer: progress, strategies, and novel adjuvants. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20143403.","journal-title":"Int J Mol Sci"},{"key":"8774_CR71","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1007\/s00262-013-1400-3","volume":"62","author":"MA Morse","year":"2013","unstructured":"Morse MA, Chaudhry A, Gabitzsch ES, Hobeika AC, Osada T, Clay TM et al. Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. Cancer Immunol Immunother 2013;62:1293\u20131301. https:\/\/doi.org\/10.1007\/s00262-013-1400-3.","journal-title":"Cancer Immunol Immunother"},{"key":"8774_CR72","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s40425-019-0576-2","volume":"7","author":"AE Snook","year":"2019","unstructured":"Snook AE, Baybutt TR, Xiang B et al. Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients. J Immunother Cancer 2019;7:104. https:\/\/doi.org\/10.1186\/s40425-019-0576-2.","journal-title":"J Immunother Cancer"},{"key":"8774_CR73","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1158\/1078-0432.CCR-05-2732","volume":"12","author":"R Harrop","year":"2006","unstructured":"Harrop R, Connolly N, Redchenko I et al. Vaccination of colorectal cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I\/II trial. Clin Cancer Res 2006;12:3416\u20133424. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-2732.","journal-title":"Clin Cancer Res"},{"key":"8774_CR74","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1097\/CJI.0b013e3181876ab3","volume":"31","author":"E Elkord","year":"2008","unstructured":"Elkord E, Dangoor A, Drury NL et al. An MVA-based vaccine targeting the oncofetal antigen 5T4 in patients undergoing surgical resection of colorectal cancer liver metastases. J Immunother 2008;31:820\u2013829. https:\/\/doi.org\/10.1097\/CJI.0b013e3181876ab3.","journal-title":"J Immunother"},{"key":"8774_CR75","doi-asserted-by":"publisher","first-page":"4843","DOI":"10.1158\/1078-0432.ccr-08-0276","volume":"14","author":"HL Kaufman","year":"2008","unstructured":"Kaufman HL, Lenz HJ, Marshall J et al. Combination chemotherapy and ALVAC-CEA\/B7.1 vaccine in patients with metastatic colorectal cancer. Clin Cancer Res 2008;14:4843\u20134849. https:\/\/doi.org\/10.1158\/1078-0432.ccr-08-0276.","journal-title":"Clin Cancer Res"},{"key":"8774_CR76","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001662","volume":"8","author":"JC Erika","year":"2020","unstructured":"Erika JC, Amy CH, Donna N et al. Long-term survival of patients with stage III colon cancer treated with VRP-CEA(6D), an alphavirus vector that increases the CD8+ effector memory T cell to Treg ratio. Journal for ImmunoTherapy of Cancer 2020;8:e001662. https:\/\/doi.org\/10.1136\/jitc-2020-001662.","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"8774_CR77","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/s1357-4310(99)01633-0","volume":"6","author":"MT Shata","year":"2000","unstructured":"Shata MT, Stevceva L, Agwale S, Lewis GK, Hone DM. Recent advances with recombinant bacterial vaccine vectors. Mol Med Today 2000;6:66\u201371. https:\/\/doi.org\/10.1016\/s1357-4310(99)01633-0.","journal-title":"Mol Med Today"},{"key":"8774_CR78","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1590\/s1517-83822014000400001","volume":"45","author":"AJ da Silva","year":"2014","unstructured":"da Silva AJ, Zangirolami TC, Novo-Mansur MT, Giordano Rde C, Martins EA. Live bacterial vaccine vectors: an overview. Braz J Microbiol 2014;45:1117\u20131129. https:\/\/doi.org\/10.1590\/s1517-83822014000400001.","journal-title":"Braz J Microbiol"},{"key":"8774_CR79","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1051\/medsci\/2007234386","volume":"23","author":"C Leclerc","year":"2007","unstructured":"Leclerc C. New technologies for vaccine development. Med Sci (Paris) 2007;23:386\u2013390. https:\/\/doi.org\/10.1051\/medsci\/2007234386.","journal-title":"Med Sci (Paris)"},{"key":"8774_CR80","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/87974","volume":"7","author":"AC Stubbs","year":"2001","unstructured":"Stubbs AC, Martin KS, Coeshott C et al. Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity. Nat Med 2001;7:625\u2013629. https:\/\/doi.org\/10.1038\/87974.","journal-title":"Nat Med"},{"key":"8774_CR81","doi-asserted-by":"publisher","first-page":"5084","DOI":"10.1158\/0008-5472.CAN-04-1487","volume":"64","author":"Y Lu","year":"2004","unstructured":"Lu Y, Bellgrau D, Dwyer-Nield LD et al. Mutation-selective tumor remission with ras-targeted, whole yeast-based immunotherapy. Cancer Res 2004;64:5084\u20135088. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-1487.","journal-title":"Cancer Res"},{"key":"8774_CR82","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00262-013-1505-8","volume":"63","author":"M Bilusic","year":"2014","unstructured":"Bilusic M, Heery CR, Arlen PM et al. Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma. Cancer Immunol Immunother 2014;63:225\u2013234. https:\/\/doi.org\/10.1007\/s00262-013-1505-8.","journal-title":"Cancer Immunol Immunother"},{"key":"8774_CR83","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/CJI.0000000000000219","volume":"41","author":"A Cohn","year":"2018","unstructured":"Cohn A, Morse MA, O\u2019Neil B et al. Whole recombinant saccharomyces cerevisiae yeast expressing ras mutations as treatment for patients with solid tumors bearing ras mutations: results from a phase 1 trial. J Immunother 2018;41:141\u2013150. https:\/\/doi.org\/10.1097\/CJI.0000000000000219.","journal-title":"J Immunother"},{"key":"8774_CR84","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1158\/2326-6066.cir-15-0119","volume":"3","author":"CR Heery","year":"2015","unstructured":"Heery CR, Singh BH, Rauckhorst M et al. Phase I trial of a yeast-based therapeutic cancer vaccine (GI-6301) targeting the transcription factor brachyury. Cancer Immunol Res 2015;3:1248\u20131256. https:\/\/doi.org\/10.1158\/2326-6066.cir-15-0119.","journal-title":"Cancer Immunol Res"},{"key":"8774_CR85","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jconrel.2021.03.037","volume":"333","author":"Y Hou","year":"2021","unstructured":"Hou Y, Liu R, Hong X et al. Engineering a sustained release vaccine with a pathogen-mimicking manner for robust and durable immune responses. J Control Release 2021;333:162\u2013175. https:\/\/doi.org\/10.1016\/j.jconrel.2021.03.037.","journal-title":"J Control Release"},{"key":"8774_CR86","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1084\/jem.121.3.439","volume":"121","author":"P Gold","year":"1965","unstructured":"Gold P, Freedman SO. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 1965;121:439\u2013462. https:\/\/doi.org\/10.1084\/jem.121.3.439.","journal-title":"J Exp Med"},{"key":"8774_CR87","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13046-019-1154-7","volume":"38","author":"A Lopes","year":"2019","unstructured":"Lopes A, Vandermeulen G, Preat V. Cancer DNA vaccines: current preclinical and clinical developments and future perspectives. J Exp Clin Cancer Res 2019;38:146. https:\/\/doi.org\/10.1186\/s13046-019-1154-7.","journal-title":"J Exp Clin Cancer Res"},{"key":"8774_CR88","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/978-1-4939-3387-7_43","volume":"1403","author":"S Thomas","year":"2016","unstructured":"Thomas S, Prendergast GC. Cancer vaccines: a brief overview. Methods Mol Biol 2016;1403:755\u2013761. https:\/\/doi.org\/10.1007\/978-1-4939-3387-7_43.","journal-title":"Methods Mol Biol"},{"key":"8774_CR89","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8030529","author":"B Gordon","year":"2020","unstructured":"Gordon B, Gadi VK. The role of the tumor microenvironment in developing successful therapeutic and secondary prophylactic breast cancer vaccines. Vaccines (Basel). 2020. https:\/\/doi.org\/10.3390\/vaccines8030529.","journal-title":"Vaccines (Basel)"},{"key":"8774_CR90","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s11427-019-9665-8","volume":"63","author":"Z Zhao","year":"2020","unstructured":"Zhao Z, Xiao X, Saw PE et al. Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment. Science China Life Sciences 2020;63:180\u2013205.","journal-title":"Science China Life Sciences"},{"key":"8774_CR91","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.3389\/fimmu.2020.01109","volume":"11","author":"A Rodriguez-Garcia","year":"2020","unstructured":"Rodriguez-Garcia A, Palazon A, Noguera-Ortega E, Powell DJ Jr, Guedan S. CAR-T cells hit the tumor microenvironment: strategies to overcome tumor escape. Front Immunol 2020;11:1109.","journal-title":"Front Immunol"},{"key":"8774_CR92","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.biologicals.2016.06.002","volume":"44","author":"T Hayakawa","year":"2016","unstructured":"Hayakawa T, Harris I, Joung J et al. Report of the international regulatory forum on human cell therapy and gene therapy products. Biologicals 2016;44:467\u2013479.","journal-title":"Biologicals"},{"key":"8774_CR93","doi-asserted-by":"publisher","DOI":"10.3390\/cells7100155","author":"C Graham","year":"2018","unstructured":"Graham C, Jozwik A, Pepper A, Benjamin R. Allogeneic CAR-T cells: more than ease of access? Cells. 2018. https:\/\/doi.org\/10.3390\/cells7100155.","journal-title":"Cells"},{"key":"8774_CR94","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.640082","volume":"12","author":"D Martinez Bedoya","year":"2021","unstructured":"Martinez Bedoya D, Dutoit V, Migliorini D. Allogeneic CAR T cells: an alternative to overcome challenges of CAR T cell therapy in glioblastoma. Front Immunol 2021;12:640082. https:\/\/doi.org\/10.3389\/fimmu.2021.640082.","journal-title":"Front Immunol"},{"key":"8774_CR95","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.7150\/jca.50509","volume":"12","author":"H Li","year":"2021","unstructured":"Li H, Yang C, Cheng H, Huang S, Zheng Y. CAR-T cells for colorectal cancer: target-selection and strategies for improved activity and safety. Journal of Cancer 2021;12:1804.","journal-title":"Journal of Cancer"},{"key":"8774_CR96","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13046-021-01970-2","volume":"40","author":"G Rizzo","year":"2021","unstructured":"Rizzo G, Bertotti A, Leto SM, Vetrano S. Patient-derived tumor models: a more suitable tool for pre-clinical studies in colorectal cancer. J Exp Clin Cancer Res 2021;40:178. https:\/\/doi.org\/10.1186\/s13046-021-01970-2.","journal-title":"J Exp Clin Cancer Res"},{"key":"8774_CR97","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3389\/fimmu.2019.00128","volume":"10","author":"M Martinez","year":"2019","unstructured":"Martinez M, Moon EK. CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment. Front Immunol 2019;10:128. https:\/\/doi.org\/10.3389\/fimmu.2019.00128.","journal-title":"Front Immunol"},{"key":"8774_CR98","doi-asserted-by":"publisher","first-page":"13545","DOI":"10.18632\/oncotarget.14592","volume":"8","author":"WX Ang","year":"2017","unstructured":"Ang WX, Li Z, Chi Z, Du S-H, Chen C, Tay JC et al. Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis. Oncotarget 2017;8:13545.","journal-title":"Oncotarget"},{"key":"8774_CR99","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.7150\/jca.50509","volume":"12","author":"H Li","year":"2021","unstructured":"Li H, Yang C, Cheng H, Huang S, Zheng Y. CAR-T cells for colorectal cancer: target-selection and strategies for improved activity and safety. J Cancer 2021;12:1804\u20131814. https:\/\/doi.org\/10.7150\/jca.50509.","journal-title":"J Cancer"},{"key":"8774_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-021-01763-9","volume":"21","author":"K-T Jin","year":"2021","unstructured":"Jin K-T, Chen B, Liu Y-Y, Lan H, Yan J-P. Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer. Cancer Cell International 2021;21:1\u201315.","journal-title":"Cancer Cell International"},{"key":"8774_CR101","doi-asserted-by":"publisher","first-page":"976","DOI":"10.3389\/fbioe.2022.797440","volume":"10","author":"A Alnefaie","year":"2022","unstructured":"Alnefaie A, Albogami S, Asiri Y et al. Chimeric antigen receptor T-cells: an overview of concepts, applications, limitations, and proposed solutions. Front Bioeng Biotechnol 2022;10:976.","journal-title":"Front Bioeng Biotechnol"},{"key":"8774_CR102","doi-asserted-by":"publisher","first-page":"1899469","DOI":"10.1080\/2162402X.2021.1899469","volume":"10","author":"SE Cha","year":"2021","unstructured":"Cha SE, YazakiKujawski MJP, Brown C, Shively JE. Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine. Oncoimmunology 2021;10:1899469.","journal-title":"Oncoimmunology"},{"key":"8774_CR103","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1016\/j.ymthe.2021.08.003","volume":"29","author":"B Akbari","year":"2021","unstructured":"Akbari B, Ghahri-Saremi N, Soltantoyeh T, Hadjati J, Ghassemi S, Mirzaei HR. Epigenetic strategies to boost CAR T cell therapy. Molecular Therapy 2021;29:2640\u20132659.","journal-title":"Molecular Therapy"},{"key":"8774_CR104","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-021-00536-x","volume":"11","author":"N Chen","year":"2021","unstructured":"Chen N, Xu Y, Mou J et al. Targeting of IL-10R on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells. Blood cancer journal 2021;11:1\u201311.","journal-title":"Blood cancer journal"},{"key":"8774_CR105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-021-04100-0","volume":"12","author":"J Xu","year":"2021","unstructured":"Xu J, Meng Q, Sun H et al. HER2-specific chimeric antigen receptor-T cells for targeted therapy of metastatic colorectal cancer. Cell Death & Disease 2021;12:1\u201311.","journal-title":"Cell Death & Disease"},{"key":"8774_CR106","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010;18:843\u2013851. https:\/\/doi.org\/10.1038\/mt.2010.24.","journal-title":"Mol Ther"},{"key":"8774_CR107","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/mt.2013.17","volume":"21","author":"CH Lamers","year":"2013","unstructured":"Lamers CH, Sleijfer S, van Steenbergen S et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther 2013;21:904\u2013912. https:\/\/doi.org\/10.1038\/mt.2013.17.","journal-title":"Mol Ther"},{"key":"8774_CR108","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9010182","author":"D Sur","year":"2020","unstructured":"Sur D, Havasi A, Cainap C et al. Chimeric antigen receptor T-cell therapy for colorectal cancer. J Clin Med. 2020. https:\/\/doi.org\/10.3390\/jcm9010182.","journal-title":"J Clin Med"},{"key":"8774_CR109","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1002\/ijc.27566","volume":"131","author":"VA Ingebrigtsen","year":"2012","unstructured":"Ingebrigtsen VA, Boye K, Tekle C, Nesland JM, Flatmark K, Fodstad O. B7\u2013H3 expression in colorectal cancer: nuclear localization strongly predicts poor outcome in colon cancer. Int J Cancer 2012;131:2528\u20132536. https:\/\/doi.org\/10.1002\/ijc.27566.","journal-title":"Int J Cancer"},{"key":"8774_CR110","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.biopha.2018.08.109","volume":"107","author":"M Guo","year":"2018","unstructured":"Guo M, You C, Dou J. Role of transmembrane glycoprotein mucin 1 (MUC1) in various types of colorectal cancer and therapies: current research status and updates. Biomed Pharmacother 2018;107:1318\u20131325. https:\/\/doi.org\/10.1016\/j.biopha.2018.08.109.","journal-title":"Biomed Pharmacother"},{"key":"8774_CR111","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/978-3-030-49270-0_4","volume":"1273","author":"C Guillerey","year":"2020","unstructured":"Guillerey C. NK cells in the tumor microenvironment. Adv Exp Med Biol 2020;1273:69\u201390. https:\/\/doi.org\/10.1007\/978-3-030-49270-0_4.","journal-title":"Adv Exp Med Biol"},{"key":"8774_CR112","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s00262-016-1792-y","volume":"65","author":"PSA Becker","year":"2016","unstructured":"Becker PSA, Suck G, Nowakowska P et al. Selection and expansion of natural killer cells for NK cell-based immunotherapy Cancer Immunology. Immunotherapy 2016;65:477\u2013484. https:\/\/doi.org\/10.1007\/s00262-016-1792-y.","journal-title":"Immunotherapy"},{"key":"8774_CR113","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.624687","volume":"12","author":"M Liu","year":"2021","unstructured":"Liu M, Liang S, Zhang C. NK cells in autoimmune diseases: protective or pathogenic? Front Immunol 2021;12:624687. https:\/\/doi.org\/10.3389\/fimmu.2021.624687.","journal-title":"Front Immunol"},{"key":"8774_CR114","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.3389\/fimmu.2018.01869","volume":"9","author":"AM Abel","year":"2018","unstructured":"Abel AM, Yang C, Thakar MS, Malarkannan S. Natural killer cells: development, maturation, and clinical utilization. Front Immunol 2018;9:1869. https:\/\/doi.org\/10.3389\/fimmu.2018.01869.","journal-title":"Front Immunol"},{"key":"8774_CR115","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.3389\/fimmu.2019.02836","volume":"10","author":"P Minetto","year":"2019","unstructured":"Minetto P, Guolo F, Pesce S et al. Harnessing NK cells for cancer treatment. Front Immunol 2019;10:2836. https:\/\/doi.org\/10.3389\/fimmu.2019.02836.","journal-title":"Front Immunol"},{"key":"8774_CR116","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3390\/ijms20020443","volume":"20","author":"MA Streltsova","year":"2019","unstructured":"Streltsova MA, Erokhina SA, Kanevskiy LM et al. Recurrent stimulation of natural killer cell clones with K562 expressing membrane-bound interleukin-21 affects their phenotype, interferon-\u03b3 production, and lifespan. Int J Mol Sci 2019;20:443.","journal-title":"Int J Mol Sci"},{"key":"8774_CR117","doi-asserted-by":"publisher","first-page":"4263520","DOI":"10.1155\/2018\/4263520","volume":"2018","author":"Q Zhang","year":"2018","unstructured":"Zhang Q, Zhang H, Ding J et al. Combination therapy with EpCAM-CAR-NK-92 cells and regorafenib against human colorectal cancer models. Journal of Immunology Research 2018;2018:4263520.","journal-title":"Journal of Immunology Research"},{"key":"8774_CR118","doi-asserted-by":"publisher","first-page":"4494","DOI":"10.1158\/1078-0432.CCR-20-0768","volume":"26","author":"S-C Lee","year":"2020","unstructured":"Lee S-C, Shimasaki N, Lim JS et al. Phase I trial of expanded, activated autologous NK-cell infusions with trastuzumab in patients with HER2-positive cancers. Clinical Cancer Research 2020;26:4494\u20134502.","journal-title":"Clinical Cancer Research"},{"key":"8774_CR119","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1002\/ijc.31285","volume":"142","author":"T Ishikawa","year":"2018","unstructured":"Ishikawa T, Okayama T, Sakamoto N et al. Phase I clinical trial of adoptive transfer of expanded natural killer cells in combination with IgG1 antibody in patients with gastric or colorectal cancer. Int J Cancer 2018;142:2599\u20132609. https:\/\/doi.org\/10.1002\/ijc.31285.","journal-title":"Int J Cancer"},{"key":"8774_CR120","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10071033","author":"M Della Chiesa","year":"2022","unstructured":"Della Chiesa M, Setti C, Giordano C et al. NK cell-based immunotherapy in colorectal cancer. Vaccines (Basel). 2022. https:\/\/doi.org\/10.3390\/vaccines10071033.","journal-title":"Vaccines (Basel)"},{"key":"8774_CR121","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40364-022-00364-6","volume":"10","author":"L Zhang","year":"2022","unstructured":"Zhang L, Meng Y, Feng X, Han Z. CAR-NK cells for cancer immunotherapy: from bench to bedside. Biomarker Research 2022;10:12. https:\/\/doi.org\/10.1186\/s40364-022-00364-6.","journal-title":"Biomarker Research"},{"key":"8774_CR122","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.ymthe.2019.03.011","volume":"27","author":"L Xiao","year":"2019","unstructured":"Xiao L, Cen D, Gan H, Sun Y, Huang N, Xiong H et al. Adoptive transfer of NKG2D CAR mRNA-engineered natural killer cells in colorectal cancer patients. Molecular Therapy 2019;27:1114\u20131125.","journal-title":"Molecular Therapy"},{"key":"8774_CR123","doi-asserted-by":"publisher","first-page":"16011","DOI":"10.1038\/mto.2016.11","volume":"3","author":"CL Bonifant","year":"2016","unstructured":"Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ. Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics 2016;3:16011. https:\/\/doi.org\/10.1038\/mto.2016.11.","journal-title":"Mol Ther Oncolytics"},{"key":"8774_CR124","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3389\/fmolb.2019.00160","volume":"6","author":"E Henke","year":"2019","unstructured":"Henke E, Nandigama R, Ergun S. Extracellular matrix in the tumor microenvironment and its impact on cancer therapy. Front Mol Biosci 2019;6:160. https:\/\/doi.org\/10.3389\/fmolb.2019.00160.","journal-title":"Front Mol Biosci"},{"key":"8774_CR125","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1172\/JCI13853","volume":"109","author":"MC Poznansky","year":"2002","unstructured":"Poznansky MC, Olszak IT, Evans RH et al. Thymocyte emigration is mediated by active movement away from stroma-derived factors. J Clin Invest 2002;109:1101\u20131110. https:\/\/doi.org\/10.1172\/JCI13853.","journal-title":"J Clin Invest"},{"key":"8774_CR126","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1158\/1535-7163.MCT-09-0583","volume":"8","author":"LG Daenen","year":"2009","unstructured":"Daenen LG, Shaked Y, Man S et al. Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models. Mol Cancer Ther 2009;8:2872\u20132881. https:\/\/doi.org\/10.1158\/1535-7163.MCT-09-0583.","journal-title":"Mol Cancer Ther"},{"key":"8774_CR127","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","volume":"33","author":"JN Kochenderfer","year":"2015","unstructured":"Kochenderfer JN, Dudley ME, Kassim SH et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2015;33:540\u2013549. https:\/\/doi.org\/10.1200\/JCO.2014.56.2025.","journal-title":"J Clin Oncol"},{"key":"8774_CR128","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac5415","author":"DL Porter","year":"2015","unstructured":"Porter DL, Hwang WT, Frey NV et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015. https:\/\/doi.org\/10.1126\/scitranslmed.aac5415.","journal-title":"Sci Transl Med"},{"key":"8774_CR129","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, Hanafi LA, Berger C et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest 2016;126:2123\u20132138. https:\/\/doi.org\/10.1172\/JCI85309.","journal-title":"J Clin Invest"},{"key":"8774_CR130","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med 2018;24:731\u2013738. https:\/\/doi.org\/10.1038\/s41591-018-0041-7.","journal-title":"Nat Med"},{"key":"8774_CR131","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","volume":"125","author":"SL Maude","year":"2015","unstructured":"Maude SL, Teachey DT, Porter DL, Grupp SA. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood 2015;125:4017\u20134023. https:\/\/doi.org\/10.1182\/blood-2014-12-580068.","journal-title":"Blood"},{"key":"8774_CR132","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer Journal 2021;11:69. https:\/\/doi.org\/10.1038\/s41408-021-00459-7.","journal-title":"Blood Cancer Journal"},{"key":"8774_CR133","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/s1470-2045(22)00197-8","volume":"23","author":"LA Diaz Jr","year":"2022","unstructured":"Diaz LA Jr, Shiu KK, Kim TW et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol 2022;23:659\u2013670. https:\/\/doi.org\/10.1016\/s1470-2045(22)00197-8.","journal-title":"Lancet Oncol"},{"key":"8774_CR134","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa071834","volume":"357","author":"DJ Jonker","year":"2007","unstructured":"Jonker DJ, O\u2019Callaghan CJ, Karapetis CS et al. Cetuximab for the treatment of colorectal cancer. New England Journal of Medicine 2007;357:2040\u20132048. https:\/\/doi.org\/10.1056\/NEJMoa071834.","journal-title":"New England Journal of Medicine"},{"key":"8774_CR135","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s11523-017-0518-1","volume":"12","author":"LS Rosen","year":"2017","unstructured":"Rosen LS, Jacobs IA, Burkes RL. Bevacizumab in colorectal cancer: current role in treatment and the potential of biosimilars. Target Oncol 2017;12:599\u2013610. https:\/\/doi.org\/10.1007\/s11523-017-0518-1.","journal-title":"Target Oncol"},{"key":"8774_CR136","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1080\/10717544.2022.2027573","volume":"29","author":"Y Liu","year":"2022","unstructured":"Liu Y, Zhang H, Cui H et al. Combined and targeted drugs delivery system for colorectal cancer treatment: conatumumab decorated, reactive oxygen species sensitive irinotecan prodrug and quercetin co-loaded nanostructured lipid carriers. Drug Deliv 2022;29:342\u2013350. https:\/\/doi.org\/10.1080\/10717544.2022.2027573.","journal-title":"Drug Deliv"},{"key":"8774_CR137","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/s1470-2045(16)00150-9","volume":"17","author":"A Sartore-Bianchi","year":"2016","unstructured":"Sartore-Bianchi A, Trusolino L, Martino C et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol 2016;17:738\u2013746. https:\/\/doi.org\/10.1016\/s1470-2045(16)00150-9.","journal-title":"Lancet Oncol"},{"key":"8774_CR138","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2023.5221","author":"G Li","year":"2023","unstructured":"Li G, Suzuki H, Ohishi T, Asano T, Tanaka T, Yanaka M et al. Antitumor activities of a defucosylated anti-EpCAM monoclonal antibody in colorectal carcinoma xenograft models. Int J Mol Med. 2023. https:\/\/doi.org\/10.3892\/ijmm.2023.5221.","journal-title":"Int J Mol Med"},{"key":"8774_CR139","doi-asserted-by":"publisher","first-page":"3557","DOI":"10.1158\/1078-0432.ccr-20-0426","volume":"26","author":"RD Kim","year":"2020","unstructured":"Kim RD, Azad NS, Morse MA et al. Phase II study of ensituximab, a novel chimeric monoclonal antibody, in adults with unresectable. Metastatic Colorectal Cancer. Clin Cancer Res 2020;26:3557\u20133564. https:\/\/doi.org\/10.1158\/1078-0432.ccr-20-0426.","journal-title":"Metastatic Colorectal Cancer. Clin Cancer Res"},{"key":"8774_CR140","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1158\/1078-0432.CCR-20-2385","volume":"27","author":"J Jiffry","year":"2021","unstructured":"Jiffry J, Thavornwatanayong T, Rao D et al. Oncolytic reovirus (pelareorep) induces autophagy in KRAS-mutated colorectal cancerautophagy augments pelareorep activity in KRAS-mutated CRC. Clinical Cancer Research 2021;27:865\u2013876.","journal-title":"Clinical Cancer Research"},{"key":"8774_CR141","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/gt.2016.15","volume":"23","author":"H Yang","year":"2016","unstructured":"Yang H, Peng T, Li J et al. Treatment of colon cancer with oncolytic herpes simplex virus in preclinical models. Gene Ther 2016;23:450\u2013459. https:\/\/doi.org\/10.1038\/gt.2016.15.","journal-title":"Gene Ther"},{"key":"8774_CR142","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1089\/hum.2017.041","volume":"28","author":"S Yuan","year":"2017","unstructured":"Yuan S, Wu Y, Wang Y, Chen J, Chu L. An oncolytic adenovirus expressing SNORD44 and GAS5 exhibits antitumor effect in colorectal cancer cells. Hum Gene Ther 2017;28:690\u2013700. https:\/\/doi.org\/10.1089\/hum.2017.041.","journal-title":"Hum Gene Ther"},{"key":"8774_CR143","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1089\/cbr.2019.3084","volume":"36","author":"J Wang","year":"2021","unstructured":"Wang J, Liu T, Chen J. Oncolytic measles virus encoding interleukin-12 mediated antitumor activity and immunologic control of colon cancer in vivo and ex vivo. Cancer Biother Radiopharm 2021;36:774\u2013782. https:\/\/doi.org\/10.1089\/cbr.2019.3084.","journal-title":"Cancer Biother Radiopharm"},{"key":"8774_CR144","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3727\/096504020x15942028641011","volume":"28","author":"L Deng","year":"2021","unstructured":"Deng L, Yang X, Fan J et al. IL-24-armed oncolytic vaccinia virus exerts potent antitumor effects via multiple pathways in colorectal cancer. Oncol Res 2021;28:579\u2013590. https:\/\/doi.org\/10.3727\/096504020x15942028641011.","journal-title":"Oncol Res"},{"key":"8774_CR145","doi-asserted-by":"publisher","DOI":"10.1007\/s002620000146","author":"H H\u00f6rig","year":"2000","unstructured":"H\u00f6rig H, Lee DS, Conkright W et al. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol Immunother. 2000. https:\/\/doi.org\/10.1007\/s002620000146.","journal-title":"Cancer Immunol Immunother"},{"key":"8774_CR146","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1089\/dna.2017.3810","volume":"36","author":"SN Danishmalik","year":"2017","unstructured":"Danishmalik SN, Sin JI. Therapeutic tumor control of HER2 DNA vaccines is achieved by an alteration of tumor cells and tumor microenvironment by gemcitabine and anti-Gr-1 Ab treatment in a HER2-expressing tumor model. DNA Cell Biol 2017;36:801\u2013811. https:\/\/doi.org\/10.1089\/dna.2017.3810.","journal-title":"DNA Cell Biol"},{"key":"8774_CR147","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cellimm.2018.04.003","volume":"329","author":"HY Son","year":"2018","unstructured":"Son HY, Apostolopoulos V, Chung JK, Kim CW, Park JU. Protective efficacy of a plasmid DNA vaccine against transgene-specific tumors by Th1 cellular immune responses after intradermal injection. Cell Immunol 2018;329:17\u201326. https:\/\/doi.org\/10.1016\/j.cellimm.2018.04.003.","journal-title":"Cell Immunol"},{"key":"8774_CR148","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.1016\/j.vaccine.2004.03.041","volume":"22","author":"SA Ali","year":"2004","unstructured":"Ali SA, Ahmad M, Lynam J et al. Anti-tumour therapeutic efficacy of OX40L in murine tumour model. Vaccine 2004;22:3585\u20133594. https:\/\/doi.org\/10.1016\/j.vaccine.2004.03.041.","journal-title":"Vaccine"},{"key":"8774_CR149","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2014.29","volume":"4","author":"RS Cross","year":"2015","unstructured":"Cross RS, Malaterre J, Davenport AJ et al. Therapeutic DNA vaccination against colorectal cancer by targeting the MYB oncoprotein. Clin Transl Immunology 2015;4:e30. https:\/\/doi.org\/10.1038\/cti.2014.29.","journal-title":"Clin Transl Immunology"},{"key":"8774_CR150","first-page":"21","volume":"2","author":"D Ockert","year":"1996","unstructured":"Ockert D, Schirrmacher V, Beck N et al. Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. Clin Cancer Res 1996;2:21\u201328.","journal-title":"Clin Cancer Res"},{"key":"8774_CR151","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1200\/JCO.2000.18.1.148","volume":"18","author":"JE Harris","year":"2000","unstructured":"Harris JE, Ryan L, Hoover HC Jr et al. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: eastern cooperative oncology group study E5283. J Clin Oncol 2000;18:148\u2013157. https:\/\/doi.org\/10.1200\/JCO.2000.18.1.148.","journal-title":"J Clin Oncol"},{"key":"8774_CR152","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/nbt0498-364","volume":"16","author":"SK Nair","year":"1998","unstructured":"Nair SK, Boczkowski D, Morse M, Cumming RI, Lyerly HK, Gilboa E. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol 1998;16:364\u2013369. https:\/\/doi.org\/10.1038\/nbt0498-364.","journal-title":"Nat Biotechnol"},{"key":"8774_CR153","doi-asserted-by":"publisher","first-page":"8809","DOI":"10.1073\/pnas.141226398","volume":"98","author":"L Fong","year":"2001","unstructured":"Fong L, Hou Y, Rivas A et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci U S A 2001;98:8809\u20138814. https:\/\/doi.org\/10.1073\/pnas.141226398.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8774_CR154","doi-asserted-by":"publisher","first-page":"2198467","DOI":"10.1080\/21645515.2023.2198467","volume":"19","author":"RO Dillman","year":"2023","unstructured":"Dillman RO, Nistor GI, Keirstead HS. Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines. Hum Vaccin Immunother 2023;19:2198467. https:\/\/doi.org\/10.1080\/21645515.2023.2198467.","journal-title":"Hum Vaccin Immunother"},{"key":"8774_CR155","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1007\/s00262-008-0477-6","volume":"57","author":"A Toubaji","year":"2008","unstructured":"Toubaji A, Achtar M, Provenzano M et al. Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers. Cancer Immunol Immunother 2008;57:1413\u20131420. https:\/\/doi.org\/10.1007\/s00262-008-0477-6.","journal-title":"Cancer Immunol Immunother"},{"key":"8774_CR156","first-page":"2044","volume":"8","author":"HM Moulton","year":"2002","unstructured":"Moulton HM, Yoshihara PH, Mason DH, Iversen PL, Triozzi PL. Active specific immunotherapy with a beta-human chorionic gonadotropin peptide vaccine in patients with metastatic colorectal cancer: antibody response is associated with improved survival. Clin Cancer Res 2002;8:2044\u20132051.","journal-title":"Clin Cancer Res"},{"key":"8774_CR157","first-page":"3950","volume":"7","author":"Y Miyagi","year":"2001","unstructured":"Miyagi Y, Imai N, Sasatomi T et al. Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides. Clin Cancer Res 2001;7:3950\u20133962.","journal-title":"Clin Cancer Res"},{"key":"8774_CR158","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1479-5876-2-19","volume":"2","author":"T Tsuruma","year":"2004","unstructured":"Tsuruma T, Hata F, Torigoe T et al. Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Transl Med 2004;2:19. https:\/\/doi.org\/10.1186\/1479-5876-2-19.","journal-title":"J Transl Med"},{"key":"8774_CR159","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1158\/1078-0432.CCR-08-2227","volume":"15","author":"FM Speetjens","year":"2009","unstructured":"Speetjens FM, Kuppen PJ, Welters MJ et al. Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin Cancer Res 2009;15:1086\u20131095. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-2227.","journal-title":"Clin Cancer Res"},{"key":"8774_CR160","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12943-023-01807-w","volume":"22","author":"M Chehelgerdi","year":"2023","unstructured":"Chehelgerdi M, Chehelgerdi M. The use of RNA-based treatments in the field of cancer immunotherapy. Molecular Cancer 2023;22:106. https:\/\/doi.org\/10.1186\/s12943-023-01807-w.","journal-title":"Molecular Cancer"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-024-08774-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-024-08774-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-024-08774-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T12:22:55Z","timestamp":1742300575000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-024-08774-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,27]]},"references-count":160,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["8774"],"URL":"https:\/\/doi.org\/10.1007\/s10620-024-08774-2","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,27]]},"assertion":[{"value":"26 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}